- Fee assured
- Verified this account
Dr Tim Illidge is an internationally recognised expert in the management of lymphoma, who has led and been involved with many early phase and late clinical trials.
Tim is involved with the central steering group of the NCRI lymphoma group and has represented the UK at numerous international meetings and workshops in lymphoma.
Completing a highly prestigious Cancer Research UK senior clinical research fellowship between 1999-2009, and holding the post of Senior Fulbright Fellow at Stanford university, California, Tim was appointed Professor of Oncology at the University of Manchester in 2004 and is currently Head of Division of Cancer Sciences at the university of Manchester, based at the Christie Hospital.
Tim leads a translational research group that is devoted to developing new anti-cancer treatments.
Areas of interest
Lymphoma; Hodgkin's disease
Current NHS consultant posts held
The Christie NHS Foundation Trust
Antibodies, antibody drug conjugates, radioimmunotherapy, radionuclide therapy
He is a keen classical guitarist, and enjoys sport, family and wine.
Tim has been an invited lecturer on aspects of lymphoma management at international meetings all over the world and has 100+ publications in this field.
Reference number 3290806
Information for healthcare professionals (Bupa patients only, last 12 months)
Clinical supervision and planning for delivery of chemotherapy cycle 1 - 21 days - (5-50)
Clinical supervision and planning for delivery of chemotherapy cycle 1 - 28 days - (5-50)
Clinical supervision of external beam radiotherapy, up to and including 15 fractions or part thereof - (1-5)
Clinical supervision of the planning of a course of complex radiotherapy - (1-5)
Preparation for rotational Intensity Modulated Radiotherapy (IMRT) (eg VMAT, RapidArc, Tomotherapy) - (1-5)
- Show All (7)...